218 related articles for article (PubMed ID: 21681114)
1. Thalidomide use and outcomes in pediatric patients with Crohn disease refractory to infliximab and adalimumab.
Felipez LM; Gokhale R; Tierney MP; Kirschner BS
J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):28-33. PubMed ID: 21681114
[TBL] [Abstract][Full Text] [Related]
2. Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.
Rosh JR; Lerer T; Markowitz J; Goli SR; Mamula P; Noe JD; Pfefferkorn MD; Kelleher KT; Griffiths AM; Kugathasan S; Keljo D; Oliva-Hemker M; Crandall W; Carvalho RS; Mack DR; Hyams JS
Am J Gastroenterol; 2009 Dec; 104(12):3042-9. PubMed ID: 19724267
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of adalimumab in pediatric patients with Crohn disease.
Wyneski MJ; Green A; Kay M; Wyllie R; Mahajan L
J Pediatr Gastroenterol Nutr; 2008 Jul; 47(1):19-25. PubMed ID: 18607264
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas.
Ng SC; Plamondon S; Gupta A; Burling D; Swatton A; Vaizey CJ; Kamm MA
Am J Gastroenterol; 2009 Dec; 104(12):2973-86. PubMed ID: 19755971
[TBL] [Abstract][Full Text] [Related]
5. Mucosal healing with thalidomide in refractory Crohn's disease patients intolerant of anti-TNF-α drugs: report of 3 cases and literature review.
Scribano ML; Cantoro L; Marrollo M; Cosintino R; Kohn A
J Clin Gastroenterol; 2014 Jul; 48(6):530-3. PubMed ID: 24667589
[TBL] [Abstract][Full Text] [Related]
6. Effect of long-term low-dose prednisone on height velocity and disease activity in pediatric and adolescent patients with Crohn disease.
Navarro FA; Hanauer SB; Kirschner BS
J Pediatr Gastroenterol Nutr; 2007 Sep; 45(3):312-8. PubMed ID: 17873743
[TBL] [Abstract][Full Text] [Related]
7. Effect of thalidomide on clinical remission in children and adolescents with refractory Crohn disease: a randomized clinical trial.
Lazzerini M; Martelossi S; Magazzù G; Pellegrino S; Lucanto MC; Barabino A; Calvi A; Arrigo S; Lionetti P; Lorusso M; Mangiantini F; Fontana M; Zuin G; Palla G; Maggiore G; Bramuzzo M; Pellegrin MC; Maschio M; Villanacci V; Manenti S; Decorti G; De Iudicibus S; Paparazzo R; Montico M; Ventura A
JAMA; 2013 Nov; 310(20):2164-73. PubMed ID: 24281461
[TBL] [Abstract][Full Text] [Related]
8. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease.
Riis A; Martinsen TC; Waldum HL; Fossmark R
Scand J Gastroenterol; 2012 Jun; 47(6):649-57. PubMed ID: 22472026
[TBL] [Abstract][Full Text] [Related]
9. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
Lozeron P; Denier C; Lacroix C; Adams D
Arch Neurol; 2009 Apr; 66(4):490-7. PubMed ID: 19364934
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of thalidomide in children and young adults with intractable inflammatory bowel disease: long-term results.
Lazzerini M; Martelossi S; Marchetti F; Scabar A; Bradaschia F; Ronfani L; Ventura A
Aliment Pharmacol Ther; 2007 Feb; 25(4):419-27. PubMed ID: 17269997
[TBL] [Abstract][Full Text] [Related]
11. An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohn's disease.
Sabate JM; Villarejo J; Lemann M; Bonnet J; Allez M; Modigliani R
Aliment Pharmacol Ther; 2002 Jun; 16(6):1117-24. PubMed ID: 12030953
[TBL] [Abstract][Full Text] [Related]
12. Infliximab improves inflammation and anthropometric measures in pediatric Crohn's disease.
Sinitsky DM; Lemberg DA; Leach ST; Bohane TD; Jackson R; Day AS
J Gastroenterol Hepatol; 2010 Apr; 25(4):810-6. PubMed ID: 20492339
[TBL] [Abstract][Full Text] [Related]
13. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients.
Swaminath A; Ullman T; Rosen M; Mayer L; Lichtiger S; Abreu MT
Aliment Pharmacol Ther; 2009 Feb; 29(3):273-8. PubMed ID: 19006540
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab therapy in children with Crohn disease previously treated with infliximab.
Cozijnsen M; Duif V; Kokke F; Kindermann A; van Rheenen P; de Meij T; Schaart M; Damen G; Norbruis O; Pelleboer R; Van den Neucker A; van Wering H; Hummel T; Oudshoorn J; Escher J; de Ridder L;
J Pediatr Gastroenterol Nutr; 2015 Feb; 60(2):205-10. PubMed ID: 25286063
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of adalimumab in moderate-to-severe pediatric Crohn's disease.
Viola F; Civitelli F; Di Nardo G; Barbato MB; Borrelli O; Oliva S; Conte F; Cucchiara S
Am J Gastroenterol; 2009 Oct; 104(10):2566-71. PubMed ID: 19550415
[TBL] [Abstract][Full Text] [Related]
16. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
Marehbian J; Arrighi HM; Hass S; Tian H; Sandborn WJ
Am J Gastroenterol; 2009 Oct; 104(10):2524-33. PubMed ID: 19532125
[TBL] [Abstract][Full Text] [Related]
17. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
Charpignon C; Beau P
Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with infliximab therapy in 100 patients with Crohn's disease.
Farrell RJ; Shah SA; Lodhavia PJ; Alsahli M; Falchuk KR; Michetti P; Peppercorn MA
Am J Gastroenterol; 2000 Dec; 95(12):3490-7. PubMed ID: 11151882
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of thalidomide therapy in pediatric Crohn's disease with evidence of tuberculosis.
Wang L; Hong Y; Wu J; Leung YK; Huang Y
World J Gastroenterol; 2017 Nov; 23(43):7727-7734. PubMed ID: 29209113
[TBL] [Abstract][Full Text] [Related]
20. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S
Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
